- Journal club critique
- Open Access
First do no harm: surrogate endpoints and the lesson of β-agonists in acute lung injury
© BioMed Central Ltd 2012
- Published: 26 June 2012
Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, Hite D, Holets S, Kallet RH, Liu KD, MacIntyre N, Moss M, Schoenfeld D, Steingrub J, Thompson BT: Randomized, placebo-controlled clinical trial of an aerosolized β-agonist for treatment of acute lung injury. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Am J Respir Crit Care Med 2011, 184: 561-568.
β2-Adrenergic receptor agonists accelerate resolution of pulmonary edema in experimental and clinical studies of acute lung injury (ALI).
Objective: To determine whether an aerosolized β2-agonist would improve clinical outcomes in patients with ALI.
Design: Multi-center, phase III randomized, placebo-controlled clinical trial.
Setting: 33 hospitals participating National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network.
Subjects: Patients who were intubated and receiving mechanical ventilation, had bilateral infiltrates consistent with edema on frontal chest radiograph, had a ratio of PaO2 to FIO2 (fraction of inspired oxygen) of 300 or less, and not had clinical evidence of left atrial hypertension. A maximum enrolment of 1,000 patients was planned.
Intervention: Patients were randomized to receive aerosolized albuterol (5 mg) or saline placebo every 4 hours for up to 10 days.
Outcomes: The primary outcome variable was ventilator-free days (VFD). Secondary outcome measures included mortality before hospital discharge on day 60 and day 90, the number of intensive care unit (ICU)-free days and the number of organ failure-free days.
There were 282 patients enrolled before the trial was stopped for futility after the second interim analysis. The VFDs difference with albuterol treatment was unfavourable by -2.2 days, well past the futility boundary of -0.4 VFDs. VFDs were not significantly different between the albuterol and placebo groups (means of 14.4 and 16.6 days, respectively; 95% confidence interval for the difference, -4.7 to 0.3 days; P = 0.087). Rates of death before hospital discharge and the number of organ failure-free days were also not significantly different between the two groups. The number of ICU-free days was lower in the albuterol group in comparison with the placebo group (means of 13.5 and 16.2 days respectively; 95% confidence intervals for the mean difference, -4.9 to -0.4 days; P = 0.023). Overall, heart rates were significantly higher in the albuterol group by approximately 5 beats/minute in the first 2 days after randomization (P < 0.05), but rates of new onset atrial fibrillation (10% in both groups) and other cardiac dysrhythmias were not significantly different.
These results suggest that aerosolized albuterol does not improve clinical outcomes in ALI patients. Routine use of β2 agonist therapy in mechanically ventilated ALI patients cannot be recommended.
Whenever we use surrogate endpoints and physiologic rationale to make decisions in patient care, investigators and clinicians should be cautious when translating the data into clinical benefit. As seen from this study, routine use of β2 adrenergic agonist in ALI cannot be recommended, since there was no benefit and a suggestion of a tendency to cause harm to patients. β2 adrenergic agonist therapy could be used as a therapeutic agent for use in patients with ALI and evidence of air flow obstruction, but not on a routine basis.
- Rubenfeld GD, Caldwell E, Peabody E, et al.: Incidence and outcomes of acute lung injury. N Engl J Med 2005, 353: 1685-1693. 10.1056/NEJMoa050333View ArticlePubMedGoogle Scholar
- Matthay MA, Folkesson HG, Clerici C: Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev 2002, 82: 569-600.View ArticlePubMedGoogle Scholar
- Sakuma T, Okaniwa G, Nakada T, et al.: Alveolar fluid clearance in the resected human lung. Am J Respir Crit Care Med 1994, 150: 305-310.View ArticlePubMedGoogle Scholar
- Perkins GD, McAuley DF, Thickett DR, et al.: The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006, 173: 281-287. 10.1164/rccm.200508-1302OCView ArticlePubMedGoogle Scholar
- National Heart, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Matthay MA, Brower RG, et al.: Randomized, placebo-controlled clinical trial of an aerosolized beta(2)-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011, 184: 561-568.View ArticleGoogle Scholar
- Gao SF, Perkins GD, Gates S, et al.: Effect of intravenous beta-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomized controlled trial. Lancet 2012, 379: 229-235. 10.1016/S0140-6736(11)61623-1View ArticleGoogle Scholar
- Fleming TR, DeMets DL: Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996, 125: 605-613.View ArticlePubMedGoogle Scholar
- Rubenfeld GD: Surrogate measures of patient-centered outcomes in critical care. Update in Intensive Care and Emergency Medicine 2003.Google Scholar